OBJECTIVE
To investigate the safety and efficacy of basiliximab as induction agent in preventing early acute rejection post heart transplantation.
METHODS
Basiliximab (20 mg, iv) was administered one hour before and 4 days post operation to patients (n = 47) underwent heart transplantation between